Insider · CIK 0001051578
David E I Pyott
Files at ALNY (ALNYLAM PHARMACEUTICALS, INC.), TARS (Tarsus Pharmaceuticals, Inc.). First filing Mar 25, 2025, latest Mar 25, 2025.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ALNY: ALNYLAM PHARMACEUTICALS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 33Weak | ALNYLAM PHARMACEUTICALS, INC. | $2.2M 7,440 shares | -98% | +25% from low-3% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Common Stockindirect: By the David E.I. Pyott Trust | +201 | - | - | 9,575 | 25 d ago |
| Sep 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -201 | $0.00 | $0 | 605 | 25 d ago |
| May 8, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | AGrant or award Common Stock | +775 | $0.00 | $0 | 911 | May 12, 2025 |
| May 8, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | AGrant or award Stock Option (right to buy)derivative | +1,558 | $0.00 | $0 | 1,558 | May 12, 2025 |
| Mar 24, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | MOption exercise Common Stock10b5-1 | +7,440 | $88.95 | $662k | 7,576 | Mar 25, 2025 |
| Mar 24, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -7,440 | $299.00 | $2.2M | 136 | Mar 25, 2025 |
| Mar 24, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -7,440 | $0.00 | $0 | 0 | Mar 25, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.